Broadening the Efficacy of Cancer Immunotherapies [ 2019 - ]

Research Grant

Researchers: A/Pr Michele Teng (Principal investigator)

Brief description Over the past 5 years, antibodies targeting immunomodulatory receptors such as Ipilimumab, Nivolumab/Pembrolizumab have been revolutionary in causing long term tumor regression and disease free survival in advanced cancers. My vision is to increase the proportion of cancer patients that will respond to immunotherapy by exploring novel pathways and combinations and optimizing their scheduling and assessing their safety in mouse models to allow their rapid translation into the clinic.

Funding Amount $483,404.00

Funding Scheme Career Development Fellowships

Notes RD Wright Biomedical CDF